GAIN THERAPEUTICS, INC.

Analyst Reco. Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Market Closed - Nasdaq Other stock markets 20:59:15 03/05/2024 BST			5-day change	1st Jan Change
2.93 ^USD	0.00%		-3.30%	-10.26%

04-24	Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287	CI
04-08	Gain Therapeutics Names Gene Mack as CFO	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Trims Price Target on Gain Therapeutics to $9 From $10, Keeps Buy Rating	12-04	MT
Maxim Starts Gain Therapeutics at Buy With $10 Price Target	12/09/23	MT
Chardan Raises Price Target on Gain Therapeutics to $6 From $5.75, Keeps Buy Rating	15/05/23	MT
Chardan Raises PT on Gain Therapeutics to $5.75 From $4 on Plans to Advance Lead Drug Candidate to Clinical Trials, Reiterates Buy Rating	27/03/23	MT
Chardan Ups Price Target on Gain Therapeutics to $5.75 From $4, as Lead Therapeutic Candidate Advances Into Clinic, Reiterates Buy Rating	27/03/23	MT
Chardan Initiates Gain Therapeutics With Buy Rating, Price Target is $4	09/12/22	MT
Oppenheimer Lowers Gain Therapeutics' Price Target to $10 From $30, Maintains Outperform Rating	25/11/22	MT
BTIG Lowers Price Target on Gain Therapeutics to $10 From $30, Maintains Buy Rating	14/11/22	MT
B. Riley Downgrades Gain Therapeutics to Neutral from Buy, Says Filing Delay of Parkinson's Disease Lead Candidate Worsens Financing Overhang; Lowers PT to $5 from $11	19/08/22	MT
B. Riley Lowers Gain Therapeutics' Price Target to $11 from $16 to Reflect Increased Long-Term Cost of Capital Amid Current Macro Conditions; Keeps Buy Rating	23/05/22	MT
B. Riley Lowers Gain Therapeutics' PT to $16 from $21 to Reflect Higher OpEx Spend Trajectory to Support Expanding Pipeline Activities, Keeps Buy Rating	29/03/22	MT
HC Wainwright Initiates Gain Therapeutics at Buy With $12 Price Target	29/03/22	MT
B. Riley Starts Gain Therapeutics at Buy with $21 PT, Encouraged by Drug Discovery Approach that Allows for Initial Focus on Lower-Risk Pipeline Programs	03/11/21	MT
GAIN THERAPEUTICS : Oppenheimer Initiates Coverage on Gain Therapeutics With Outperform Rating, $30 Price Target	12/04/21	MT
GAIN THERAPEUTICS : BTIG Research Initiates Coverage on Gain Therapeutics With Buy Rating, $30 Price Target	12/04/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer